Cargando…

BRAF(V600E)-induced KRT19 expression in thyroid cancer promotes lymph node metastasis via EMT

Keratin 19 (KRT19) is a type I cytokeratin that serves an important role in multiple types of cancer; however, little is known regarding its role in thyroid cancer. Therefore, the aim of the current study was to investigate the role of KRT19 in thyroid cancer. Using The Cancer Genome Atlas database,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xuhong, Xu, Xiaoqin, Peng, Chen, Qin, Yanchao, Gao, Taihu, Jing, Jiexian, Zhao, Hongcai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539636/ https://www.ncbi.nlm.nih.gov/pubmed/31289571 http://dx.doi.org/10.3892/ol.2019.10360

Ejemplares similares

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

Deep Small RNA Sequencing of BRAF V600E Mutated Papillary Thyroid Carcinoma With Lymph Node Metastasis
por: Yusof, Azliana Mohamad, et al.
Publicado: (2019)

Predicting factors of central lymph node metastasis and BRAF(V600E) mutation in Chinese population with papillary thyroid carcinoma
por: Zhou, Sheng Li, et al.
Publicado: (2021)

Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis
por: Ren, Haoyu, et al.
Publicado: (2018)

Integrating BRAF(V600E) mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma
por: Zhang, Zheng, et al.
Publicado: (2022)

The Predicting Role of Serum TSGF and sIL-2R for the Lymph Node Metastasis of Papillary Thyroid Carcinoma
por: Xu, Xiaoqin, et al.
Publicado: (2022)

BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account
por: Dong, Si-Yang, et al.
Publicado: (2017)

The thyroid imaging reporting and data system on US, but not the BRAF(V600E) mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC
por: Park, Vivian Y., et al.
Publicado: (2016)

Prediction of cervical lymph node metastasis with contrast-enhanced ultrasound and association between presence of BRAF(V600E) and extrathyroidal extension in papillary thyroid carcinoma
por: Zhan, Jia, et al.
Publicado: (2020)

Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
por: Issa, Peter P., et al.
Publicado: (2022)

A multivariable model of BRAF(V600E) and ultrasonographic features for predicting the risk of central lymph node metastasis in cN0 papillary thyroid microcarcinoma
por: Chen, Bao-Ding, et al.
Publicado: (2019)

Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer
por: Li, Ruoxuan, et al.
Publicado: (2021)

Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with BRAF(V600E) Mutation and Clinicopathological Features
por: Li, Gui-you, et al.
Publicado: (2020)

Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma
por: Zhou, Changxin, et al.
Publicado: (2019)

Real-Time PCR Cycle Threshold Values for the BRAF(V600E) Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study
por: Park, Vivian Y., et al.
Publicado: (2015)

Response to Letter to the Editor From Boucai et al: “BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer”
por: Xing, Mingzhao
Publicado: (2022)

KRT6A Promotes EMT and Cancer Stem Cell Transformation in Lung Adenocarcinoma
por: Yang, Bin, et al.
Publicado: (2020)

BRAF(V600E) Mutation-Responsive miRNA-222-3p Promotes Metastasis of Papillary Thyroid Cancer Cells via Snail-Induced EMT
por: Gao, Yuan, et al.
Publicado: (2022)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
por: Han, Ying, et al.
Publicado: (2022)

Younger Than 55 Years Old and BRAF V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm
por: Lai, Yeqian, et al.
Publicado: (2023)

Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma
por: Guo, Liang, et al.
Publicado: (2019)

Integrating US-guided FNAB, BRAF(V600E) mutation, and clinicopathologic characteristics to predict cervical central lymph-node metastasis in preoperative patients with cN0 papillary thyroid carcinoma
por: Ma, Ning, et al.
Publicado: (2023)

MON-530 Local Lymph Node Metastasis Is Less Common in RAS- Mutated Thyroid Cancer Compared to BRAFV600E- Mutated Thyroid Cancer
por: Endo, Mayumi, et al.
Publicado: (2020)

KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis
por: Wang, Wenlong, et al.
Publicado: (2020)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia
por: Zhou, Dehua, et al.
Publicado: (2018)

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Preoperative BRAF(V600E) mutation detection in thyroid carcinoma by immunocytochemistry
por: Swan, Kristine Zøylner, et al.
Publicado: (2022)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules
por: Rowe, Leslie R, et al.
Publicado: (2006)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer
por: Robbins, Richard J., et al.
Publicado: (2020)

Artificial intelligence to predict the BRAF(V600E) mutation in patients with thyroid cancer
por: Yoon, Jiyoung, et al.
Publicado: (2020)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

Induction of the BRAF(V600E) Mutation in Thyroid Cells Leads to Frequent Hypermethylation
por: Yi, Jin Wook, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4j1bdf86324oq230uu911f0l5p